Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All quercetin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchQuercetinQuercetin (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Efficiency of quercetin and trimetasidine in patients with COVID-19 and concomitant chronic coronary syndrome: effect on systemic inflammation

Tomyn et al., Bulletin of Problems Biology and Medicine, doi:10.29254/2077-4214-2024-2-173-274-280
Apr 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Quercetin for COVID-19
23rd treatment shown to reduce risk in July 2021
 
*, now with p = 0.0031 from 11 studies.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments. c19early.org
Prospective study of 92 hospitalized patients with COVID-19 and chronic coronary syndrome showing potential benefit with quercetin and trimetazidine. The quercetin group showed a 35% decrease in the SIRI inflammatory index (p=0.007), while the combination of quercetin and trimetazidine produced a 45% decrease (p=0.002), compared to a 39% increase in the control group. The combination therapy also reduced ALT and AST levels and increased estimated glomerular filtration rate. Authors do not report clinical outcomes.
Bioavailability. Quercetin has low bioavailability and studies typically use advanced formulations to improve bioavailability which may be required to reach therapeutic concentrations.
Tomyn et al., 30 Apr 2024, retrospective, peer-reviewed, 2 authors. Contact: ihor.tomyn@gmail.com.
This PaperQuercetinAll
EFFICIENCY OF QUERCETIN AND TRIMETASIDINE IN PATIENTS WITH COVID-19 AND CONCOMITANT CHRONIC CORONARY SYNDROME: EFFECT ON SYSTEMIC INFLAMMATION
I V Tomyn, S V Fedorov
Bulletin of Problems Biology and Medicine, doi:10.29254/2077-4214-2024-2-173-274-280
Patients with cardiovascular disease suffer a more severe course of COVID-19, requiring enhanced oxygen therapy, including invasive methods, and higher mortality. At the same time, SARS-CoV2 can directly or indirectly adversely affect the course of chronic coronary syndromes, independent of the use of optimal treatment. The use of quercetin in combination with trimetazidine promises new opportunities for the treatment of patients with COVID-19 with concomitant cardiovascular disease, offering an integrated approach to reduce inflammation, oxidative stress, and improve heart muscle function. Quercetin can help reduce symptoms, shorten the duration of the disease and prevent the development of complications, especially in patients with CVD. Trimetazidine, on the other hand, acts as a metabolic modulator of the heart muscle, optimizing oxygen consumption and improving the energy metabolism of cardiomyocytes. In the context of COVID-19, this may help maintain cardiac function in patients with concomitant CVD, reducing the risk of developing heart failure and other complications. The aim of the study was to evaluate the efficacy of quercetin and its combination with trimetazidine compared to standard therapy for the treatment of pneumonia associated with COVID-19 and concomitant chronic coronary syndromes. For the study, 92 patients with COVID-19 and concomitant chronic coronary syndromes were selected and divided into three groups: the first group received only standard treatment (n=31), the second group received additional quercetin intravenously for 7 days (n=29), and the third group received quercetin in combination with trimetazidine for 7 days (n=32). The study of inflammatory markers revealed that the combination of quercetin with trimetazidine reduces inflammatory activity, which is reflected in a decrease in the SIRI and AISI inflammation indices (p<0.001). There was also a decrease in transaminase activity and an improvement in the level of GFR.
КЛІНІЧНА ТА ЕКСПЕРИМЕНТАЛЬНА МЕДИЦИНА / CLINICAL AND EXPERIMENTAL MEDICINE EFFICIENCY OF QUERCETIN AND TRIMETASIDINE IN PATIENTS WITH COVID-19 AND CONCOMITANT CHRONIC CORONARY SYNDROME: EFFECT ON SYSTEMIC INFLAMMATION Tomyn I. V., Fedorov S. V. Abstract. Cardiovascular diseases increase the risk of severe coronavirus disease, causing a greater need for oxygen support, including invasive oxygen support, and higher mortality in such patients. At the same time, the SARS-Cov2 virus directly or indirectly worsens the course of atherosclerotic cardiovascular disease, despite optimal drug therapy. The combined use of quercetin and trimetazidine may be a promising direction in the treatment of patients with COVID-19 and concomitant CVD, offering a comprehensive approach to reducing inflammation, oxidative stress and improving the metabolic state of the heart muscle. The aim of the study was to determine the efficacy of quercetin and the combination of quercetin and trimetazidine in comparison with baseline therapy in pneumonia associated with COVID-19 and background chronic coronary syndromes. Object and methods. We selected 92 patients with COVID-19-associated pneumonia and concomitant chronic coronary syndromes (CCS), who were divided into 3 groups. The first group received only baseline therapy (n=31), the second group received quercetin 0.5 g as an intravenous infusion for 7 days in addition to baseline therapy (n=29), and the third group received a combination of quercetin and..
References
Cheema, Sohail, Fatima, Shahid, Shahzil et al., Quercetin for the treatment of COVID-19 patients: A systematic review and meta-analysis, Reviews in Medical Virology, doi:10.1002/rmv.2427
Derosa, Maffioli, Angelo, Pierro, A role for quercetin in coronavirus disease 2019 (COVID-19), Phytotherapy Research, doi:10.1002/ptr.6887
Huang, Deng, Li, Sun, Chen et al., Clinical characteristics and drug therapies in patients with the common-type coronavirus disease 2019 in Hunan, China, International journal of clinical pharmacy, doi:10.1007/s11096-020-01031-2
Pierro, Khan, Iqtadar, Mumtaz, Chaudhry et al., Quercetin as a possible complementary agent for earlystage COVID-19: Concluding results of a randomized clinical trial, Frontiers in pharmacology, doi:10.3389/fphar.2022.1096853
Saeedi-Boroujeni, Mr, Anti-inflammatory potential of Quercetin in COVID-19 treatment, Journal of Inflammation, doi:10.1186/s12950-021-00268-6
Salinas, Travieso, Vergara-Uzcategui, Tirado-Conte, Macaya et al., Clinical profile and 30-day mortality of invasively managed patients with suspected acute coronary syndrome during the COVID-19 outbreak, International Heart Journal, doi:10.1536/ihj.20-574
Shu, Peng, Hang, Zhou, Trimetazidine in heart failure, Frontiers in Pharmacology, doi:10.3389/fphar.2020.569132
Williams, Jureka, Silvas, Nicolini, Chvatal et al., Inhibitors of VPS34 and fatty-acid metabolism suppress SARS-CoV-2 replication, Cell Rep, doi:10.1016/j.celrep.2021.109479
Wu, Deng, Yu, Han, Huang et al., Evaluation of the efficacy and safety of Chinese herbal injection combined with trimetazidine for viral myocarditis: a network meta-analysis, Frontiers in Pharmacology, doi:10.3389/fphar.2021.630896
{ 'indexed': {'date-parts': [[2024, 6, 28]], 'date-time': '2024-06-28T00:21:28Z', 'timestamp': 1719534088812}, 'reference-count': 9, 'publisher': 'Poltava State Medical University', 'issue': '1', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2024]]}, 'DOI': '10.29254/2077-4214-2024-2-173-274-280', 'type': 'journal-article', 'created': {'date-parts': [[2024, 6, 27]], 'date-time': '2024-06-27T18:15:33Z', 'timestamp': 1719512133000}, 'page': '274', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'EFFICIENCY OF QUERCETIN AND TRIMETASIDINE IN PATIENTS WITH COVID-19 AND CONCOMITANT CHRONIC ' 'CORONARY SYNDROME: EFFECT ON SYSTEMIC INFLAMMATION', 'prefix': '10.29254', 'volume': '1', 'author': [ { 'given': 'I. V.', 'family': 'Tomyn', 'sequence': 'first', 'affiliation': [ { 'name': 'Ivano-Frankivsk National Medical University (Ivano-Frankivsk, ' 'Ukraine)'}]}, { 'given': 'S. V.', 'family': 'Fedorov', 'sequence': 'additional', 'affiliation': [ { 'name': 'Ivano-Frankivsk National Medical University (Ivano-Frankivsk, ' 'Ukraine)'}]}], 'member': '11800', 'reference': [ { 'key': '10.29254/2077-4214-2024-2-173-274-280-1', 'doi-asserted-by': 'crossref', 'unstructured': 'Cheema HA, Sohail A, Fatima A, Shahid A, Shahzil M, Ur Rehman ME, et al. ' 'Quercetin for the treatment of COVID-19 patients: A\n' 'systematic review and meta-analysis. Reviews in Medical Virology. 2023 ' 'Mar;33(2):e2427. DOI: 10.1002/rmv.2427.', 'DOI': '10.1002/rmv.2427'}, { 'key': '10.29254/2077-4214-2024-2-173-274-280-2', 'doi-asserted-by': 'crossref', 'unstructured': 'Di Pierro F, Khan A, Iqtadar S, Mumtaz SU, Chaudhry MN, Bertuccioli A, ' 'et al. Quercetin as a possible complementary agent for earlystage ' 'COVID-19: Concluding results of a randomized clinical trial. Frontiers ' 'in pharmacology. 2023 Jan 13;13:1096853. DOI: 10.3389/\n' 'fphar.2022.1096853.', 'DOI': '10.3389/fphar.2022.1096853'}, { 'key': '10.29254/2077-4214-2024-2-173-274-280-3', 'doi-asserted-by': 'crossref', 'unstructured': 'Saeedi-Boroujeni A, Mahmoudian-Sani MR. Anti-inflammatory potential of ' 'Quercetin in COVID-19 treatment. Journal of Inflammation.\n' '2021 Dec;18:1-9. DOI: 10.1186/s12950-021-00268-6.', 'DOI': '10.1186/s12950-021-00268-6'}, { 'key': '10.29254/2077-4214-2024-2-173-274-280-4', 'doi-asserted-by': 'crossref', 'unstructured': 'Derosa G, Maffioli P, Dâ\x80\x99Angelo A, Di Pierro F. A role for ' 'quercetin in coronavirus disease 2019 (COVID-19). Phytotherapy Research. ' '2021\n' 'Mar;35(3):1230-6. DOI: 10.1002/ptr.6887.', 'DOI': '10.1002/ptr.6887'}, { 'key': '10.29254/2077-4214-2024-2-173-274-280-5', 'doi-asserted-by': 'crossref', 'unstructured': 'Huang Q, Deng X, Li Y, Sun X, Chen Q, Xie M, et al. Clinical ' 'characteristics and drug therapies in patients with the common-type\n' 'coronavirus disease 2019 in Hunan, China. International journal of ' 'clinical pharmacy. 2020 Jun;42:837-45. DOI: 10.1007/s11096-020-\n' '01031-2.', 'DOI': '10.1007/s11096-020-01031-2'}, { 'key': '10.29254/2077-4214-2024-2-173-274-280-6', 'doi-asserted-by': 'crossref', 'unstructured': 'Williams CG, Jureka AS, Silvas JA, Nicolini AM, Chvatal SA, ' 'Carlson-Stevermer J, et al. Inhibitors of VPS34 and fatty-acid ' 'metabolism\n' 'suppress SARS-CoV-2 replication. Cell Rep. 2021 Aug 3;36(5):109479. DOI: ' '10.1016/j.celrep.2021.109479.', 'DOI': '10.1016/j.celrep.2021.109479'}, { 'key': '10.29254/2077-4214-2024-2-173-274-280-7', 'doi-asserted-by': 'crossref', 'unstructured': 'Salinas P, Travieso A, Vergara-Uzcategui C, Tirado-Conte G, Macaya F, ' 'MejÃ\xada-RenterÃ\xada H, et al. Clinical profile and 30-day mortality ' 'of\n' 'invasively managed patients with suspected acute coronary syndrome ' 'during the COVID-19 outbreak. International Heart Journal. 2021\n' 'Mar 30;62(2):274-81. DOI: 10.1536/ihj.20-574.', 'DOI': '10.1536/ihj.20-574'}, { 'key': '10.29254/2077-4214-2024-2-173-274-280-8', 'doi-asserted-by': 'crossref', 'unstructured': 'Wu K, Deng D, Yu B, Han Z, Huang L, He Y, et al. Evaluation of the ' 'efficacy and safety of Chinese herbal injection combined with ' 'trimetazidine\n' 'for viral myocarditis: a network meta-analysis. Frontiers in ' 'Pharmacology. 2021 Apr 29;12:630896. DOI: 10.3389/fphar.2021.630896.', 'DOI': '10.3389/fphar.2021.630896'}, { 'key': '10.29254/2077-4214-2024-2-173-274-280-9', 'doi-asserted-by': 'crossref', 'unstructured': 'Shu H, Peng Y, Hang W, Zhou N. Trimetazidine in heart failure. Frontiers ' 'in Pharmacology. 2021 Jan 12;11:569132. DOI: 10.3389/\n' 'fphar.2020.569132.', 'DOI': '10.3389/fphar.2020.569132'}], 'container-title': 'Bulletin of Problems Biology and Medicine', 'original-title': [], 'language': 'en', 'deposited': { 'date-parts': [[2024, 6, 27]], 'date-time': '2024-06-27T18:37:10Z', 'timestamp': 1719513430000}, 'score': 1, 'resource': { 'primary': { 'URL': 'https://vpbim.com.ua/knowledgebase/efficiency-of-quercetin-and-trimetasidine-in-patients-with-covid-19-and-concomitant-chronic-coronary-syndrome-effect-on-systemic-inflammation/'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2024]]}, 'references-count': 9, 'journal-issue': {'issue': '1', 'published-print': {'date-parts': [[2024]]}}, 'alternative-id': ['2077-4214-2024-2-173-274-280'], 'URL': 'http://dx.doi.org/10.29254/2077-4214-2024-2-173-274-280', 'relation': {}, 'ISSN': ['2077-4214', '2523-4110'], 'subject': [], 'container-title-short': 'VPBM', 'published': {'date-parts': [[2024]]}}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit